- Targeted stakeholdersRaises national public awareness of Barth syndrome, increasing visibility for patients, caregivers, and clinicians.
- Targeted stakeholdersMay encourage earlier diagnosis and referral to specialized clinics and multidisciplinary care teams.
- Targeted stakeholdersCould attract research interest and philanthropic funding toward ultrarare disease studies and therapy development.
Expressing support for the designation of April 5, 2026, as "Barth Syndrome Awareness Day".
Referred to the House Committee on Energy and Commerce.
This House resolution expresses support for designating April 5, 2026, as Barth Syndrome Awareness Day.
It explains Barth syndrome’s clinical features, prevalence, and challenges, notes the need for research and diagnostics, and recognizes relevant actors like the Barth Syndrome Foundation and Kennedy Krieger Institute.
The resolution also highlights the role of the Orphan Drug Act and FDA patient-focused programs and encourages attention to regulatory pathways for ultrarare disease drug development.
Text is a nonbinding House resolution that does not create law; adoption by the House likely, but it cannot become law as written.
Relative to its intended legislative type, this bill functions as a conventional commemorative resolution: it provides a substantive factual preamble and then issues declarative support for designating April 5, 2026 as Barth Syndrome Awareness Day while listing awareness and research priorities. The level of operational, fiscal, and legal detail is minimal but appropriate for a symbolic designation.
Left emphasizes need for funding and access commitments
Who stands to gain, and who may push back.
- Targeted stakeholdersThe resolution is symbolic and creates no new funding, legal mandates, or entitlement programs.
- Targeted stakeholdersUnlikely to produce immediate clinical treatments, FDA approvals, or measurable health outcomes.
- Targeted stakeholdersMay raise patient and caregiver expectations for rapid policy or therapeutic advances without resources.
Why the argument around this bill splits.
Left emphasizes need for funding and access commitments
Likely welcomes the resolution as a compassionate, patient-centered recognition of a rare disease and a prompt to accelerate research.
Would emphasize the need for federal support, equitable access to care, and incorporating patient perspectives into drug development.
Likely supportive of the nonbinding, awareness-focused resolution while wanting clear limits on fiscal or regulatory commitments.
Views it as a reasonable, low-cost way to spotlight unmet medical needs, but seeks practical follow-up steps.
Generally supportive of an awareness day for a rare, life-threatening disease but cautious about language implying regulatory or budgetary change.
Prefers symbolic recognition without new federal obligations or expanded bureaucratic programs.
The path through Congress.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Text is a nonbinding House resolution that does not create law; adoption by the House likely, but it cannot become law as written.
- Whether House will adopt by voice or need recorded vote
- Existence or filing of a companion Senate resolution
Recent votes on the bill.
No vote history yet
The bill has not accumulated any surfaced votes yet.
Go deeper than the headline read.
Left emphasizes need for funding and access commitments
Text is a nonbinding House resolution that does not create law; adoption by the House likely, but it cannot become law as written.
Relative to its intended legislative type, this bill functions as a conventional commemorative resolution: it provides a substantive factual preamble and then issues declarative support for designating April 5, 2026 as…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.